Drug intelligence / Profile preview

NAV-340

Development stage: Preclinical
Lead developer: Navigator Medicines
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

NAV-340 is a preclinical bispecific antibody being developed by Navigator Medicines. It is designed to target OX40 ligand (OX40L; TNFSF4) and an undisclosed second target. The drug is intended for the treatment of inflammatory and type 2 immune-mediated diseases, specifically atopic dermatitis and asthma. By dual-targeting OX40L and another inflammatory mediator, NAV-340 aims to modulate immune responses more effectively than single-target therapies. As of early 2024, the candidate remains in the preclinical stage of development, with asthma noted as a potential indication pending further investment decisions.

Targets

TNFSF4 (Tumor necrosis factor ligand superfamily member 4)

Beyond the preview

Go deeper on NAV-340.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NAV-340.

Explore the full profile